HROW

Harrow, Inc. (HROW) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers Harrow, Inc.'s unaudited financial results for the quarter ended March 31, 2026. Harrow is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic products in the U.S. market. The company operates through two primary segments: Branded (FDA-approved ophthalmic products) and Compounding (ophthalmology-focused pharmaceutical compounding via ImprimisRx).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 7.6% year-over-year. The Compounding segment saw a significant drop of 32.7% ($6.6 million decrease) due to lower volume and the discontinuation of the Klarity-C formulation. The Branded segment increased 10.5% ($2.9 million increase), driven by growth in "Other branded products," which offset declines in IHEEZO and VEVYE.
• Margin Compression: Gross margin declined from 67.5% to 61.2%. The Branded segment margin fell to 64.3% due to higher gross-to-net deductions (rebates/chargebacks) associated with VEVYE coverage wins. The Compounding segment margin dropped to 54.0% due to lower facility utilization.
• Increased Expenses: Operating expenses rose to $49.1 million from $43.5 million. Selling, General, and Administrative (SG&A) expenses increased by $2.7 million, primarily due to higher personnel costs ($3.8 million increase) to support growth. R&D expenses more than doubled to $5.9 million, driven by clinical trials for the Melt Pharmaceuticals drug candidate acquired in late 2025.
• Debt Financing: In March 2026, the company issued an additional $50 million in 8.625% Senior Notes due 2030, bringing total principal debt to $300 million. Net proceeds were approximately $48.5 million.

Outlook, Risks, and Unusual Items

• Liquidity: Management believes current cash of $94.6 million is sufficient to fund operations for at least the next 12 months. The company has a $40 million revolving line of credit (with an uncommitted $20 million accordion) that remains undrawn.
• Legal Contingency: The company holds a $11.2 million judgment against Ocular Science, Inc. (OSRX) following a jury verdict in late 2024. However, due to an ongoing appeal by OSRX and uncertainty regarding collection, no amount has been recognized in the financial statements.
• Regulatory Risks: The filing highlights risks related to government reimbursement pressures, including potential "most-favored-nation" pricing policies under the Inflation Reduction Act and proposed CMS demonstration models (GLOBE/GUARD) that could impact ophthalmic product pricing.
• Capital Expenditures: Significant investing cash outflows of $18.2 million were recorded, primarily for the purchase of product rights ($18 million), including settlements and milestones for Santen and Samsung Bioepis agreements.

Investor Verification Checklist

• Debt Service Capacity: Verify the company's ability to service $300 million in debt with an 8.625% coupon (approx. $25.9 million annual interest) given the current operating loss trajectory.
• Rebate Accruals: Review the adequacy of the $67.6 million in accrued rebates and chargebacks, as changes in these estimates directly impact net revenue and gross margin.
• Compounding Segment Viability: Assess the long-term impact of the Klarity-C discontinuation and the ability to replace lost volume in the Compounding segment.
• Legal Recovery: Monitor the status of the OSRX appeal to determine if the $11.2 million judgment will be collected or written off.
• R&D Pipeline: Evaluate the progress and cost trajectory of the Melt Pharmaceuticals drug candidate, which is driving the recent spike in R&D spend.